# High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

> **NCT03494270** · PHASE4 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 270 (actual)

## Conditions studied

- ASCVD

## Interventions

- **DRUG:** Rosuvamibe
- **DRUG:** Monorova

## Key facts

- **NCT ID:** NCT03494270
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-18
- **Primary completion:** 2019-09-26
- **Final completion:** 2019-09-26
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03494270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03494270, "High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03494270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*